Anzeige
Mehr »
Samstag, 27.09.2025 - Börsentäglich über 12.000 News
Das Paradox-Becken hat sich bewiesen - und American Critical sitzt direkt auf dem nächsten Milliardenfund
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLTL | ISIN: US86150R1077 | Ticker-Symbol: 0GT
Tradegate
25.09.25 | 17:52
19,500 Euro
-5,34 % -1,100
1-Jahres-Chart
STOKE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
STOKE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
20,60021,00013:02
20,20020,80026.09.

Aktuelle News zur STOKE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.09.Biogen Inc.: Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome409- Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies - - Substantial...
► Artikel lesen
02.09.Stoke Therapeutics, Inc.: Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome381- Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies - -...
► Artikel lesen
25.08.Biogen Inc.: Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress432- 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard...
► Artikel lesen
25.08.Stoke Therapeutics, Inc.: Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress375- 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard...
► Artikel lesen
18.08.Stoke Therapeutics stock price target lowered to $28 at BTIG on Zorevunersen data2
13.08.Where Stoke Therapeutics Stands With Analysts12
12.08.Stoke Therapeutics, Inc. - 10-Q, Quarterly Report2
12.08.Stoke Therapeutics GAAP EPS of -$0.40 beats by $0.13, revenue of $13.8M beats by $8.56M2
STOKE THERAPEUTICS Aktie jetzt für 0€ handeln
11.08.A Look Ahead: Stoke Therapeutics' Earnings Forecast1
11.08.Biogen Inc.: Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome494- Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period - - Dravet syndrome is a rare genetic disease characterized by...
► Artikel lesen
11.08.Stoke Therapeutics, Inc. - 8-K, Current Report1
22.07.Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome23
18.07.Jefferies stuft Stoke Therapeutics mit "Buy" ein - Hohes Potenzial bei Epilepsie-Medikament11
18.07.Jefferies initiates Stoke Therapeutics stock with Buy rating on epilepsy drug potential3
14.07.Stoke Therapeutics stock maintains Buy rating at H.C. Wainwright on positive study data2
10.07.Biogen Inc.: Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress489- Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 - - These findings support...
► Artikel lesen
10.07.Stoke Therapeutics, Inc. - 8-K, Current Report1
09.07.Stoke Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
04.06.Stoke Therapeutics, Inc. - 8-K, Current Report2
15.05.Stoke Therapeutics stock target cut to $35 by H.C. Wainwright5
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1